

ASX Release

25th March 2014

Cancer Trial Application with Royal Adelaide Hospital

PharmAust Limited ("PharmAust") (ASX: PAA & PAAO) is pleased to announce that it has submitted an application to the Cancer Clinical Trials Unit of the Royal Adelaide Hospital to begin evaluation of proprietary drug PPL-1 in a Phase I/II clinical trial. Subject to consideration and approval by the Investigational Drugs Subcommittee and the Research Ethics Committee, the trial will commence recruiting patients with treatment refractory solid tumours.

As a "First in Man" study, the trial will primarily focus on the safety and pharmacokinetics of the drug, however, the evaluation is being undertaken in late stage cancer patients and as such the clinical team under the supervision of Professor Michael Brown (Principal Investigator) will also have the opportunity to determine the effects of PPL-1 on the cancer itself. A series of tumour markers indicative of tumour growth and progression will be measure during the treatment period. Furthermore, the patient tumours will be biopsied where possible and also studied with the aid of a CT-PET scanner. The study will look at increasing doses of PPL-1 in cohorts of patients with each dose being administered daily for a period of 28 days.

The cancer patients receiving PPL-1 will have failed "Standard of Care" for their respective cancers. Furthermore, as a "First in Man" study, PPL-1 will be administered to patients suffering from a variety of cancers potentially including the major cancers such as lung, pancreas, oesophageal, gastric, colorectal, ovarian, breast, prostate, liver, sarcoma, lymphoma, and melanoma.

PharmAust's Executive Chairman, Dr Roger Aston said, "We are excited about the prospects of evaluating PPL-1 in cancer patients, we also remain quite confident that the drug has a high level of safety judging by the fact that it is already in commercial use as an anti-parasitic agent in sheep and cattle." Dr Aston also added, "We are grateful and acknowledge NewSouth Innovations in this discovery and their continued support of the work emanating from the St George Hospital".

The cancer chemotherapy market (estimated at \$42 billion/annum)* is currently the fastest growing sector within the pharma industry, mainly driven by the identification of new potential therapeutic targets. This growth is further fuelled by the magnitude of the disease worldwide, currently estimated at more than 25 million people suffering from cancer globally, and an estimated 5 million people dying each year from the disease.

*Reference: Research and Markets.com accessed 14th February 2014:

http://www.researchandmarkets.com/reports/335548/chemotherapy_market_insights_20062016_a

For further details please contact:

Dr Roger Aston
Executive Chairman
PharmAust Limited
Tel: 0402 762 204

www.pharmaust.com